Targeted Oncology16u
Mirvetuximab Shows Lasting Survival Benefit in Resistant Ovarian Cancer
Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...
March 2025 Letter to Shareholders
VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, ...
CytoDyn Inc.: March 2025 Letter to Shareholders
Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. ("CytoDyn" or the "Company"). On February 24, 2025 ...